In this study, we discovered that temsirolimus (TEM), an FDA-approved anti-cancer drug, inhibits the biogenesis and secretion of sEV and sEV PD-L1 by activating autophagy in breast cancer cells, such as MDA-MB-231 cells. Here, CD274 is linked to breast carcinoma.